CTLA4 and clear cell renal carcinoma: Furthermore, immune checkpoint inhibitors, encompassing those targeting CTLA-4 and PD-1, have demonstrated their capacity to incite tumorigenic reactions within the realm of renal clear cell carcinoma (71, 72).